Tradestie Institutional Equity Comparison Engine
EXYN vs MDCX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MDCX Overall Edge
MDCX Captures Institutional Edge (2โ0 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, EXYN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus MDCX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EXYN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EXYN N/M vs MDCX N/M Fwd P/E
Growth & Margin Winner
MDCX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
MDCX
1Y -70.0% vs -49.3% ยท 52W Pos 2% vs 23%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
EXYN
US Equity
EXYN
Institutional Equity
$1.56
-9.57% 1D
Market Cap
N/A
1M Return
-46.02%
1Y Return
-70.0%
Forward P/E
N/M
Unified AI Score
50.1 / 100
HOLD
Tech 53.0
Fund 52.0
Flow 50.0
Mom 60.0
MDCX
NASDAQ
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.14
-2.16% 1D
Market Cap
$3.1M
1M Return
-56.68%
1Y Return
-49.33%
Forward P/E
N/M
Unified AI Score
49.2 / 100
HOLD
Tech 40.0
Fund 48.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EXYN -70.0%
MDCX -49.33%
Spread: +347.08 pp (MDCX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EXYN TTM Op. Margin: N/A
MDCX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EXYN vs MDCX. Trailing 12-month operating profitability (EXYN N/A vs MDCX 0.0%) and valuation multiples (EXYN N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EXYN | MDCX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $3.1M | Larger Scale | MDCX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | MDCX |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | MDCX |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | MDCX |
| Return on Equity (ROE) Capital Efficiency | N/A | -7446.1% | Higher ROE | MDCX |
| 52-Week Range Position Momentum | 2% ($1โ$7) | 23% ($0โ$5) | Stronger Trend | MDCX |
| Beta / 30D Volatility Risk Regime | 1.90ฮฒ ยท 85% Vol | -0.28ฮฒ ยท 118% Vol | Lower Realized Risk | EXYN |
| Unified Institutional Score Composite Signal | 50.1 / 100 (HOLD) | 49.2 / 100 (HOLD) | Higher Composite | EXYN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EXYN vs MDCX Buy Guide
EXYN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
MDCX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EXYN nor MDCX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.